Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study

BACKGROUND AND OBJECTIVES: Idarucizumab is an antibody fragment that specifically reverses dabigatran-mediated anticoagulation. Safety, pharmacokinetics and pharmacodynamics of idarucizumab were investigated in dabigatran-treated, middle-aged, elderly and renally impaired volunteers with characteris...

Descripción completa

Detalles Bibliográficos
Autores principales: Glund, Stephan, Stangier, Joachim, van Ryn, Joanne, Schmohl, Michael, Moschetti, Viktoria, Haazen, Wouter, De Smet, Marina, Gansser, Dietmar, Norris, Stephen, Lang, Benjamin, Reilly, Paul, Kreuzer, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222901/
https://www.ncbi.nlm.nih.gov/pubmed/27317414
http://dx.doi.org/10.1007/s40262-016-0417-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5222901/
https://www.ncbi.nlm.nih.gov/pubmed/27317414
http://dx.doi.org/10.1007/s40262-016-0417-0

Ejemplares similares